NEO
NeoGenomics, Inc. [NEO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NEO Stock Summary
Top 10 Correlated ETFs
NEO
Top 10 Correlated Stocks
NEO
In the News
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know
The consensus price target hints at a 29.6% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript
NeoGenomics, Inc (NEO) Q4 2023 Earnings Call Transcript
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.06 per share a year ago.
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc., will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.
Best Momentum Stocks to Buy for January 9th
NEO, WIX and LNW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.
New Strong Buy Stocks for January 9th
NEO, WIX, LNW, TM and RBB have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS). RaDaR data will be presented during a Poster Spotlight Session featuring an updated analysis of the TRACER study, which assessed patients with early-stage breast cancer across multiple subtypes and the potential utility of using RaDaR in this setting, including for baseline detection, for monitoring therapy response in the neoadjuvant setting, and for post-operative recurrence monitoring.
NEO Financial details
NEO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.07 | 4.09 | 4.04 | 4.1 | 4.71 | |
| Net income per share | 0.08 | 0.04 | -0.07 | -1.16 | -0.7 | |
| Operating cash flow per share | 0.23 | 0.01 | -0.22 | -0.53 | -0.02 | |
| Free cash flow per share | 0.03 | -0.25 | -0.76 | -0.78 | -0.24 | |
| Cash per share | 1.72 | 2.73 | 4.3 | 3.53 | 3.31 | |
| Book value per share | 5.05 | 6.39 | 9.24 | 8.03 | 7.5 | |
| Tangible book value per share | 1.81 | 3.34 | 1.16 | 0.54 | 0.36 | |
| Share holders equity per share | 5.05 | 6.39 | 9.24 | 8.03 | 7.5 | |
| Interest debt per share | 1.36 | 2.07 | 5.15 | 4.93 | 4.93 | |
| Market cap | 2.94B | 5.85B | 4.09B | 1.15B | 2.03B | |
| Enterprise value | 2.9B | 5.84B | 4.39B | 1.5B | 2.3B | |
| P/E ratio | 367.07 | 1.4K | -490.37 | -7.96 | -23.08 | |
| Price to sales ratio | 7.19 | 13.15 | 8.45 | 2.25 | 3.43 | |
| POCF ratio | 125.75 | 4K | -153.17 | -17.39 | -1.04K | |
| PFCF ratio | 879.86 | -211.53 | -45.05 | -11.85 | -66.13 | |
| P/B Ratio | 5.79 | 8.42 | 3.69 | 1.15 | 2.16 | |
| PTB ratio | 5.79 | 8.42 | 3.69 | 1.15 | 2.16 | |
| EV to sales | 7.09 | 13.13 | 9.06 | 2.93 | 3.89 | |
| Enterprise value over EBITDA | 75 | 173.72 | 101.23 | -17.83 | -352.79 | |
| EV to operating cash flow | 124.04 | 4K | -164.24 | -22.66 | -1.18K | |
| EV to free cash flow | 867.85 | -211.15 | -48.3 | -15.44 | -74.9 | |
| Earnings yield | 0 | 0 | 0 | -0.13 | -0.04 | |
| Free cash flow yield | 0 | 0 | -0.02 | -0.08 | -0.02 | |
| Debt to equity | 0.26 | 0.31 | 0.55 | 0.61 | 0.65 | |
| Debt to assets | 0.19 | 0.22 | 0.33 | 0.35 | 0.36 | |
| Net debt to EBITDA | -1.04 | -0.31 | 6.83 | -4.15 | -41.29 | |
| Current ratio | 4.55 | 6.13 | 7.81 | 6.73 | 6.2 | |
| Interest coverage | 2.26 | -0.3 | -1.97 | -101.66 | -15.6 | |
| Income quality | 2.92 | 0.35 | 3.2 | 0.46 | 0.02 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.31 | 0.32 | 0.46 | 0.48 | 0.41 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.05 | 0.06 | 0.05 | |
| Intangibles to total assets | 0.46 | 0.34 | 0.52 | 0.54 | 0.53 | |
| Capex to operating cash flow | -0.86 | -19.93 | 2.4 | 0.47 | 14.72 | |
| Capex to revenue | -0.05 | -0.07 | -0.13 | -0.06 | -0.05 | |
| Capex to depreciation | -0.66 | -0.81 | -1.2 | -0.44 | -0.4 | |
| Stock based compensation to revenue | 0.02 | 0.02 | 0.05 | 0.05 | 0.04 | |
| Graham number | 3.01 | 2.35 | 3.8 | 14.49 | 10.88 | |
| ROIC | 0.03 | 0 | 0 | -0.08 | -0.06 | |
| Return on tangible assets | 0.02 | 0.01 | -0.01 | -0.18 | -0.11 | |
| Graham Net | 0.49 | 0.89 | -1.25 | -1.63 | -1.71 | |
| Working capital | 226.83M | 375.55M | 594.28M | 515.36M | 500.51M | |
| Tangible asset value | 182.17M | 362.56M | 138.84M | 67M | 45.64M | |
| Net current asset value | 88.64M | 154.69M | -79.99M | -136.72M | -142.88M | |
| Invested capital | 0.26 | 0.31 | 0.55 | 0.61 | 0.65 | |
| Average receivables | 85.58M | 100.54M | 109.49M | 115.92M | 125.47M | |
| Average payables | 33.94M | 57.73M | 41.65M | 50.6M | 51.81M | |
| Average inventory | 11.53M | 21.97M | 26.46M | 23.84M | 24.22M | |
| Days sales outstanding | 84.14 | 87.74 | 84.5 | 85.72 | 80.96 | |
| Days payables outstanding | 86.24 | 92.29 | 22 | 94.45 | 21.39 | |
| Days of inventory on hand | 24.8 | 41.68 | 28.73 | 27.53 | 25.41 | |
| Receivables turnover | 4.34 | 4.16 | 4.32 | 4.26 | 4.51 | |
| Payables turnover | 4.23 | 3.95 | 16.59 | 3.86 | 17.07 | |
| Inventory turnover | 14.72 | 8.76 | 12.71 | 13.26 | 14.37 | |
| ROE | 0.02 | 0.01 | -0.01 | -0.14 | -0.09 | |
| Capex per share | -0.2 | -0.27 | -0.53 | -0.25 | -0.23 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.11 | 1.1 | 1.17 | 1.21 | 1.24 | |
| Net income per share | -0.18 | -0.25 | -0.19 | -0.15 | -0.11 | |
| Operating cash flow per share | -0.03 | -0.1 | -0.01 | -0.04 | 0.14 | |
| Free cash flow per share | -0.07 | -0.18 | -0.07 | -0.08 | 0.09 | |
| Cash per share | 3.51 | 3.34 | 3.27 | 3.2 | 3.3 | |
| Book value per share | 8 | 7.79 | 7.63 | 7.54 | 7.48 | |
| Tangible book value per share | 0.54 | 0.42 | 0.34 | 0.34 | 0.36 | |
| Share holders equity per share | 8 | 7.79 | 7.63 | 7.54 | 7.48 | |
| Interest debt per share | 4.89 | 4.87 | 4.84 | 4.8 | 4.87 | |
| Market cap | 1.15B | 2.18B | 2.01B | 1.55B | 2.04B | |
| Enterprise value | 1.5B | 2.51B | 2.33B | 1.85B | 2.31B | |
| P/E ratio | -12.7 | -17.67 | -20.7 | -20.87 | -35.56 | |
| Price to sales ratio | 8.31 | 15.86 | 13.71 | 10.17 | 13.1 | |
| POCF ratio | -312.72 | -171.5 | -1.3K | -281.24 | 114.57 | |
| PFCF ratio | -140.21 | -96.23 | -222.79 | -158.22 | 189.94 | |
| P/B Ratio | 1.15 | 2.23 | 2.11 | 1.63 | 2.16 | |
| PTB ratio | 1.15 | 2.23 | 2.11 | 1.63 | 2.16 | |
| EV to sales | 10.82 | 18.3 | 15.89 | 12.14 | 14.83 | |
| Enterprise value over EBITDA | -64.35 | -318.95 | -425.47 | -1.02K | 266.52 | |
| EV to operating cash flow | -407.08 | -197.87 | -1.51K | -335.71 | 129.71 | |
| EV to free cash flow | -182.52 | -111.03 | -258.24 | -188.87 | 215.04 | |
| Earnings yield | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Free cash flow yield | -0.01 | -0.01 | 0 | -0.01 | 0.01 | |
| Debt to equity | 0.61 | 0.63 | 0.64 | 0.64 | 0.65 | |
| Debt to assets | 0.35 | 0.36 | 0.36 | 0.36 | 0.36 | |
| Net debt to EBITDA | -14.92 | -42.51 | -58.4 | -165.26 | 31.1 | |
| Current ratio | 6.73 | 6.75 | 6.16 | 6.32 | 6.2 | |
| Interest coverage | 28.89 | 20.72 | 11.84 | 8.52 | -11.05 | |
| Income quality | 0.16 | 0.41 | 0.06 | 0.3 | -1.24 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.42 | 0.45 | 0.41 | 0.4 | 0.38 | |
| Research and developement to revenue | 0.05 | 0.05 | 0.05 | 0.03 | 0.05 | |
| Intangibles to total assets | 0.54 | 0.54 | 0.54 | 0.54 | 0.53 | |
| Capex to operating cash flow | 1.23 | 0.78 | 4.84 | 0.78 | -0.4 | |
| Capex to revenue | -0.03 | -0.07 | -0.05 | -0.03 | -0.05 | |
| Capex to depreciation | -0.25 | -0.56 | -0.41 | -0.24 | -0.38 | |
| Stock based compensation to revenue | 0.03 | 0.03 | 0.04 | 0.05 | 0.04 | |
| Graham number | 5.72 | 6.57 | 5.77 | 5 | 4.37 | |
| ROIC | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | |
| Return on tangible assets | -0.03 | -0.04 | -0.03 | -0.02 | -0.02 | |
| Graham Net | -1.62 | -1.72 | -1.78 | -1.73 | -1.7 | |
| Working capital | 515.36M | 498.39M | 489.87M | 494.02M | 500.51M | |
| Tangible asset value | 67M | 52.22M | 42.73M | 42.75M | 45.64M | |
| Net current asset value | -136.72M | -149.72M | -154.2M | -143.86M | -142.88M | |
| Invested capital | 0.61 | 0.63 | 0.64 | 0.64 | 0.65 | |
| Average receivables | 115.85M | 119.28M | 122.13M | 129.03M | 131.93M | |
| Average payables | 48.49M | 81.46M | 83.56M | 52.15M | 18.58M | |
| Average inventory | 24.04M | 24.35M | 24.69M | 24.5M | 24.1M | |
| Days sales outstanding | 77.68 | 77.95 | 76.83 | 78.56 | 75.93 | |
| Days payables outstanding | 91.54 | 86.97 | 90.47 | 16.89 | 20.8 | |
| Days of inventory on hand | 26.68 | 26.68 | 25.8 | 24.15 | 24.72 | |
| Receivables turnover | 1.16 | 1.15 | 1.17 | 1.15 | 1.19 | |
| Payables turnover | 0.98 | 1.03 | 0.99 | 5.33 | 4.33 | |
| Inventory turnover | 3.37 | 3.37 | 3.49 | 3.73 | 3.64 | |
| ROE | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | |
| Capex per share | -0.04 | -0.08 | -0.06 | -0.03 | -0.06 |
NEO Frequently Asked Questions
What is NeoGenomics, Inc. stock symbol ?
NeoGenomics, Inc. is a US stock , located in Fort myers of Fl and trading under the symbol NEO
What is NeoGenomics, Inc. stock quote today ?
NeoGenomics, Inc. stock price is $13.81 today.
Is NeoGenomics, Inc. stock public?
Yes, NeoGenomics, Inc. is a publicly traded company.
Company Profile
- Volume Average 909.49K
- Market Capitalization 1.8B
- Employee 2.1K
- CEO Mr. Christopher Michael Smith BSc
- Headquarters Fort Myers,FL,US
- IPO Date 2004-03-16
-
Website
https://www.neogenomics.com 
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
